07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

GrayBug, Aerie Pharmaceuticals deal

The companies will apply GrayBug’s polymer-based delivery technology to Aerie’s AR-13154 , which is in preclinical testing to treat wet age-related macular degeneration (AMD). AR-13154 is an inhibitor of rho-associated coiled-coil containing protein kinase (ROCK),...